Literature DB >> 10357692

Increased risk for fetal loss in carriers of the factor V Leiden mutation.

J R Meinardi1, S Middeldorp, P J de Kam, M M Koopman, E C van Pampus, K Hamulyák, M H Prins, H R Büller, J van der Meer.   

Abstract

BACKGROUND: An increased risk for fetal loss caused by placental thrombosis is probable in carriers of the factor V Leiden mutation but has not been demonstrated consistently in previous studies.
OBJECTIVE: To determine the overall risk for fetal loss and the separate risks for miscarriage and stillbirth in carriers of the factor V Leiden mutation.
DESIGN: Retrospective cohort study.
SETTING: Three university hospitals. PARTICIPANTS: 228 carriers of the factor V Leiden mutation (77 propositi, 151 relatives) and 121 noncarrier relatives (controls). All participants had been pregnant at least once. MEASUREMENTS: Risks for fetal loss, miscarriage (defined as fetal loss within 20 weeks of gestation), and stillbirth (defined as fetal loss after >20 weeks of gestation) in women and in pregnancies were estimated and compared in carriers and noncarriers. Adjusted odds ratios were calculated by using multiple regression analysis. A random-effects model was used for comparisons of pregnancies.
RESULTS: Fetal loss occurred in 31.6% of carriers and 22.3% of noncarriers, miscarriage occurred in 29.4% of carriers and 17.4% of noncarriers, and stillbirth occurred in 5.7% of carriers and 5.0% of noncarriers. Fetal loss recurred in 10.1% of carriers and 4.1% of noncarriers (odds ratio, 2.60 [95% CI, 0.96 to 7.03]). Adjusted odds ratios were 2.12 (CI, 1.35 to 3.33) for fetal loss, 2.08 (CI, 1.33 to 3.25) for miscarriage, and 1.60 (CI, 0.58 to 4.43) for still-birth when pregnancies in carriers and noncarriers were compared. Homozygous carriers had a greater risk for fetal loss (odds ratio, 2.01 [CI, 0.94 to 4.32]) and stillbirth (odds ratio, 4.85 [CI, 0.82 to 25.58]) than heterozygous carriers.
CONCLUSIONS: Carriers of the factor V Leiden mutation have a greater risk for fetal loss (particularly miscarriage) than noncarriers. These data further suggest a greater risk for recurrence of fetal loss in carriers than in noncarriers and a greater risk for fetal loss and stillbirth in homozygous carriers than in heterozygous carriers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10357692     DOI: 10.7326/0003-4819-130-9-199905040-00013

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  9 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  The cost-benefit ratio of screening pregnant women for thrombophilia.

Authors:  Gian Luca Salvagno; Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Massimo Franchi; Gian Cesare Guidi
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

Review 3.  Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia.

Authors:  Paulien G de Jong; Stef Kaandorp; Marcello Di Nisio; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2014-07-04

Review 4.  Inherited thrombophilia: a double-edged sword.

Authors:  Saskia Middeldorp
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  Postoperative pulmonary embolism in a young female accompanying with Factor V Leiden mutation and hereditary sypherocytosis.

Authors:  Demet Karnak; Sumru Beder; Oya Kayacan; Ozlem Berk
Journal:  J Thromb Thrombolysis       Date:  2004-06       Impact factor: 2.300

Review 6.  The effect of factor V Leiden carriage on maternal and fetal health.

Authors:  Dena Bloomenthal; Peter von Dadelszen; Robert Liston; Laura Magee; Peter Tsang
Journal:  CMAJ       Date:  2002-07-09       Impact factor: 8.262

Review 7.  The role of thrombophilia in pregnancy.

Authors:  Elisabeth M Battinelli; Ariela Marshall; Jean M Connors
Journal:  Thrombosis       Date:  2013-12-18

8.  Deep venous thrombosis in the antenatal period in a large cohort of pregnancies from western India.

Authors:  Sonal Vora; Kanjaksha Ghosh; Shrimati Shetty; Vinita Salvi; Purnima Satoskar
Journal:  Thromb J       Date:  2007-07-04

9.  Intrauterine upper limb ischemia: an unusual presentation of fetal thrombophilia-a case report and review of the literature.

Authors:  Samer Abdelrazeq; Abdullatif Alkhateeb; Hani Saleh; Haitham Alhasan; Hatem Khammash
Journal:  Case Rep Pediatr       Date:  2013-10-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.